The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...

Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...

Hims & Hers Health shares tumbled nearly 35% Monday after Novo Nordisk said it is pulling out of its partnership with the ...

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

Hims & Hers一直依赖复方制剂业务 —— 该业务去年占其收入的 15%—— 作为向投资者推介的增长故事的一部分。该公司指控诺和诺德强迫其 “引导” 患者使用品牌药 Wegovy，而诺和诺德则指控Hims & Hers引导患者使用未经批准的复方或 “仿冒” 药物。 Hims & Hers首席执行官安德鲁・杜杜姆（Andrew Dudum）在社交平台 X 上发帖称：“最近几周，诺和诺德的商业团 ...

The breakup between Hims & Hers and Novo Nordisk has hit HIMS stock hard with a 35% crash. Click here for a full investment ...

Investing.com - 在制药巨头诺和诺德公司 (Novo Nordisk) (NYSE: NVO )宣布将终止与该远程医疗公司关于减肥药销售的合作后，Hims & Hers Health (NYSE: HIMS )股价暴跌20%。

First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 29.2% in the morning session after Novo ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

It’s not often that investors come across the kind of companies that can yield a multi-bagger investment over the years.

In this video, I will explain why Hims & Hers Health (NYSE: HIMS) crashed over 30% on Monday. Watch the short video to learn more, consider subscribing, and click the special offer link below. *Stock ...